Upsized offering delivers $100M payoff to argenx as another biotech joins the IPO parade
The Dutch antibody shop argenx is the latest biotech to join the growing IPO parade on Nasdaq.
The biotech raised $100 million on the sale of 5.9 million shares at $17 each. And that reflects an increase of more than 2 million shares over what the company had initially planned to offer.
Argenx will trade under the ARGX symbol and CEO Tim Van Hauwermeiren gets to ring the opening bell today to celebrate the IPO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.